erlotinib hydrochloride has been researched along with Hepatorenal Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saif, MW | 1 |
| Abu-Khalaf, M; Gunturu, KS; Saif, MW | 1 |
2 other study(ies) available for erlotinib hydrochloride and Hepatorenal Syndrome
| Article | Year |
|---|---|
Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Hepatorenal Syndrome; Humans; Liver Failure; Product Surveillance, Postmarketing; Protein Kinase Inhibitors; Quinazolines | 2008 |
Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Hepatorenal Syndrome; Humans; Liver Failure; Male; Pancreatic Neoplasms; Quinazolines | 2010 |